Carl G. Klutke, M.D.

Ongoing Research

Funding Agency: Eli Lilly
Title: Protocol F1J-MC-SBBO: Efficacy and Safety of Duloxetine Compared with Placebo in Women with Symptoms of Mixed Urinary Incontinence
Period: 1/19/03-present
Role: PI

Funding Agency: Alza Corporation/J&J
Title: A Randomized, Double-Blind, Placebo-Controlled Parallel Group Evaluation of the Efficacy and Tolerability of Two Different Doses of ELMIRON® for the Treatment of Interstitial Cystitis
Period: 10/15/03-present
Role: PI

Funding Agency: Boston Scientific
Title: A Prospective, Single-Arm, Multicenter, Non-Significant Risk Clinical Study to Evaluate a Mid-Urethral Vaginal Tape Procedures With a Pre-Pubic Delivery Approach, for the Treatment of Stress Urinary Incontinence
Period: 5/19/04-present
Role: PI

Funding Agency: Mentor Corporation
Title: A Prospective, Multi-Center Study on the Efficacy and Safety of a Trans-Obturator Tape Urethral Sling in Women with Stress Urinary Incontinence
Period: 7/21/04-present
Role: PI

Funding Agency: Novartis
Title: A 12-Week, Randomized, Open-label, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Enablex® (Darifenacin) (with voluntary up titration from 7.5mg O.D. to 15 mg O.D. at week 2) Alone or in Combination with Behavioral Modification Program for Symptoms of Overactive Bladder
Period: 4/2005-present
Role: PI

Funding Agency: Investigator initiated
Title: Pudendal Nerve Stimulation for Urinary Urgency Frequency Disorders
Period: 08/04/04-present
Role: PI

Funding Agency: Pfizer, Inc
Title: A Multicenter, Multiphase, Single Arm, Open Label Study to Evaluate the Effects of Tolterodine ER in Conjunction with Behavioral Intervention on Subject Satisfaction and Overactive Bladder Symptoms (Urgency, Urinary Incontinence (UUI), Urgency, Frequency) in Overactive Bladder Subjects who were Dissatisfied with Their Most Recent Antimuscarinic OAB Medication Therapy

Dr. Carl G. Klutke's CV